Needham & Company LLC Reaffirms "Buy" Rating for BioCryst Pharmaceuticals (NASDAQ:BCRX)

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report)'s stock had its "buy" rating reissued by Needham & Company LLC in a research note issued on Thursday,Benzinga reports. They presently have a $15.00 price objective on the biotechnology company's stock. Needham & Company LLC's price target suggests a potential upside of 106.61% from the stock's current price.

Other equities analysts also recently issued reports about the company. Royal Bank of Canada reissued an "outperform" rating and set a $11.00 target price (up from $10.00) on shares of BioCryst Pharmaceuticals in a research note on Tuesday, February 25th. Evercore ISI raised their target price on BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the company an "outperform" rating in a report on Monday, January 13th. Wedbush assumed coverage on shares of BioCryst Pharmaceuticals in a research note on Tuesday, February 25th. They set an "outperform" rating and a $15.00 price target on the stock. JMP Securities reiterated a "market outperform" rating and issued a $18.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Friday, January 31st. Finally, HC Wainwright reiterated a "buy" rating and set a $30.00 price target on shares of BioCryst Pharmaceuticals in a research report on Tuesday, February 25th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $15.57.

BioCryst Pharmaceuticals Trading Up 3.1 %

Shares of BioCryst Pharmaceuticals stock traded up $0.22 during trading hours on Thursday, hitting $7.26. 1,362,274 shares of the company were exchanged, compared to its average volume of 2,794,171. The business has a 50-day moving average of $7.93 and a 200-day moving average of $7.74. BioCryst Pharmaceuticals has a 1 year low of $4.03 and a 1 year high of $9.50. The stock has a market capitalization of $1.52 billion, a price-to-earnings ratio of -11.90 and a beta of 1.75.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last released its earnings results on Monday, February 24th. The biotechnology company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.06). The firm had revenue of $131.50 million for the quarter, compared to the consensus estimate of $126.64 million. During the same period in the previous year, the business earned $0.28 EPS. The business's revenue for the quarter was up 40.8% on a year-over-year basis. As a group, research analysts anticipate that BioCryst Pharmaceuticals will post -0.36 earnings per share for the current fiscal year.

Institutional Investors Weigh In On BioCryst Pharmaceuticals

Several large investors have recently made changes to their positions in BCRX. Vanguard Group Inc. boosted its position in shares of BioCryst Pharmaceuticals by 7.8% in the fourth quarter. Vanguard Group Inc. now owns 21,890,422 shares of the biotechnology company's stock worth $164,616,000 after buying an additional 1,583,826 shares during the period. Geode Capital Management LLC boosted its stake in shares of BioCryst Pharmaceuticals by 2.7% in the third quarter. Geode Capital Management LLC now owns 4,837,985 shares of the biotechnology company's stock valued at $36,776,000 after purchasing an additional 127,708 shares during the period. Caligan Partners LP grew its holdings in BioCryst Pharmaceuticals by 16.0% during the 4th quarter. Caligan Partners LP now owns 2,995,932 shares of the biotechnology company's stock valued at $22,529,000 after purchasing an additional 412,347 shares in the last quarter. Two Sigma Advisers LP lifted its holdings in BioCryst Pharmaceuticals by 14.6% in the 4th quarter. Two Sigma Advisers LP now owns 2,499,812 shares of the biotechnology company's stock worth $18,799,000 after buying an additional 318,800 shares in the last quarter. Finally, Northern Trust Corp boosted its position in BioCryst Pharmaceuticals by 7.7% in the 4th quarter. Northern Trust Corp now owns 2,004,911 shares of the biotechnology company's stock valued at $15,077,000 after buying an additional 143,986 shares during the last quarter. Institutional investors and hedge funds own 85.88% of the company's stock.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.